Taken together, these primary human cell data indicate that FASN inhibition directly attenuates pathways of fibrogenesis and inflammation relevant to NASH, as well as reducing steatosis. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatohepatitis.